E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
acute exacerbation of COPD; acute exacerbation (defined solely by clinical parameters according to the Anthonisen criteria, meaning ≥2 of the following: change of baseline dyspnea, change of cough, change of sputum quantity or purulence) of their previously diagnosed COPD (irreversible obstruction with FEV1/FVC<70%) |
|
E.1.1.1 | Medical condition in easily understood language |
COPD is a type of obstructive lung disease characterized by long-term breathing problems and poor airflow. The main symptoms include shortness of breath and cough with sputum production.
|
|
E.1.1.2 | Therapeutic area | Diseases [C] - Respiratory Tract Diseases [C08] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10010953 |
E.1.2 | Term | COPD exacerbation |
E.1.2 | System Organ Class | 100000004855 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of this study is to investigate in an outpatient setting whether a three day treatment with orally administered systemic corticosteroids is non-inferior to a five day treatment in acute exacerbation of COPD. First endpoint will be time to next exacerbation during index exacerbation or a six months follow-up time. We postulate that in an outpatient setting, where generally less severe exacerbations are being treated, a three day treatment duration of systemic corticosteroids should be non-inferior to a five day treatment duration with regard to treatment benefits but decrease cumulative corticosteroid exposure. |
|
E.2.2 | Secondary objectives of the trial |
Secondary objective is to evaluate the two different corticosteroid treatment durations for differences in parameters other than re-exacerbation assessing effectiveness and safety. Parameters to be evaluated as secondary endpoints are: cumulative steroid dose, glucocorticoid side effects and complications, change in FEV1, clinical course assessed with the CAT-questionnaire, need for hospitalisation during index exacerbation and during follow-up time and death from any cause. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Informed Consent as documented by signature - Age ≥40 years - History of ≥10 pack-years of smoking (past or present smokers) - Airway obstruction, defined as FEV1/FVC≤70% - Current acute exacerbation of COPD by clinical criteria, defined by the presence of at least two of the following: o Change of baseline dyspnea o Change of cough o Change of sputum quantity or purulence |
|
E.4 | Principal exclusion criteria |
- Asthma/COPD overlap syndrome with a predominant Asthma component - Initial necessity of hospitalization - Women who are pregnant or breast feeding - Premenopausal women with insufficient contraception and anamnestic risk for pregnancy - Severe coexisting disease with life expectancy <6 months - Diagnosis of tuberculosis - Known severe immunosuppression or immunosuppression after solid organ or stem cell transplantation - Inability to follow study procedures, e.g. due to language problems, psychological disorders, dementia, etc. of the participant - Participation in another study involving an investigational drug - Previous enrolment into the current study |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Primary outcome measured is time to next exacerbation during index exacerbation (treatment failure) or during a six months follow-up period (whichever occurs first). Exacerbation is defined as acute-onset worsening of the patient’s condition beyond day-to-day variations requiring interaction with a healthcare provider. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Primary outcome measured is time to next exacerbation during index exacerbation (treatment failure) or during a six months follow-up period (whichever occurs first). |
|
E.5.2 | Secondary end point(s) |
Secondary study outcomes are cumulative glucocorticoid dose, glucocorticoid side effects and complications, change in FEV1, hospitalization rate during index exacerbation and during follow-up time as well as clinical outcome assessed by the CAT and overall mortality. Cumulative glucocorticoid dose and glucocorticoid side effects are assessed to investigate safety of short-term and standard steroid treatment duration. Change in FEV1, hospitalization rate during index exacerbation and during follow-up time as well as clinical outcome and overall mortality are assessed to compare effectiveness of different durations of systemic corticosteroid treatment. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 50 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
last visit of last subject |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 6 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 6 |
E.8.9.2 | In all countries concerned by the trial months | 6 |